Omeros Corporation (0KBU)
LSE
Closed
Aug 27, 2026
Day's Range
18.0052 wk Range
3.97Overview - 0KBU - Omeros Corporation
Key Statistics
Valuation
Enterprise Value
1.49B
P/E (Trailing)
‪0.05‬
EV / EBITDA
‪-20.85‬
Profitability
Profit Margin
‪324.88%‬
Operating Margin
‪0.25%‬
Return on Assets
‪-18.67%‬
Ownership
Shares Outstanding
49.00M
Float
69.28M
Held by Insiders
‪4.08%‬
Held by Institutions
‪50.60%‬
Price stats
Beta
‪2.53‬
50-Day Avg
‪3.74‬
200-Day Avg
‪4.07‬
Peers - 0KBU - Omeros Corporation
Peer Comparison
Compared with companies in Biotechnology listed on LSE.
- 0KBULSEOmeros Corporation897.94MMarket Cap+75.74%52-week change0.06P/E (Trailing)‪324.88%‬Profit Margin
- 0MGBLSEGenmab A/S173.25BMarket Cap+25.66%52-week change29.69P/E (Trailing)‪29.01%‬Profit Margin
- 0QZULSEVertex Pharmaceuticals Incorporated140.42BMarket Cap+29.13%52-week change0.58P/E (Trailing)‪34.99%‬Profit Margin
- 0R2MLSERegeneron Pharmaceuticals, Inc.88.95BMarket Cap+28.43%52-week change0.12P/E (Trailing)‪27.86%‬Profit Margin
- 0A45LSEModerna, Inc.72.19BMarket Cap+83.60%52-week change50.90P/E (Trailing)‪11.32%‬Profit Margin
- 0QW0LSEargenx SE52.72BMarket Cap+32.98%52-week change42.51P/E (Trailing)‪-47.51%‬Profit Margin
- 0NZTLSEUCB SA44.89BMarket Cap+8.61%52-week change131.85P/E (Trailing)‪6.45%‬Profit Margin
Profile Summary - 0KBU - Omeros Corporation
About
Omeros Corporation is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics. It targets large-market opportunities as well as orphan indications, particularly in areas such as inflammation, coagulopathies, disorders of the central…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
